drugset / Trial / NCT04414969
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.
Timeline
- Start
- 2020-06-26
- Primary completion
- 2022-07-01
- Completion
- 2025-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegaspargase | Protein / enzyme biologic | 2500 unknown | Intramuscular |
| Subject | Tucidinostat | Small molecule | 30 mg | Oral |